Get the Stockscreener App
2.74
1.79%
-0.05
After Hours:
2.73
-0.01
-0.36%
Immutep Limited Adr stock is traded at $2.74, with a volume of 93,187.
It is down -1.79% in the last 24 hours and down -10.75% over the past month.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$2.79
Open:
$2.8
24h Volume:
93,187
Relative Volume:
0.14
Market Cap:
$403.31M
Revenue:
-
Net Income/Loss:
$-39.57M
P/E Ratio:
-10.08
EPS:
-0.2718
Net Cash Flow:
$-39.53M
1W Performance:
+4.58%
1M Performance:
-10.75%
6M Performance:
+61.18%
1Y Performance:
+37.69%
1-Day Range:
$2.69
$2.80
1-Week Range:
$2.56
$2.825
52-Week Range:
$1.32
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
2.74 | 410.67M | 0 | -39.57M | -39.53M | -0.2718 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC - GlobeNewswire Inc.
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Immutep reports positive phase I data for first-in-class autoimmune antibody IMP761 - MSN
Why Immutep Limited (Common Stock) (YP1A) stock is trending on social mediaHealthcare Stock Analysis & Investment Portfolio Recommendations - Bollywood Helpline
Immutep (IMMP) reports positive IMP761 Phase I study update - Stock Titan
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely - Sahm
Will Immutep Limited Depositary Receipt stock see insider buying2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Why Immutep Limited (YP1B) stock is a strong analyst pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - Улправда
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - setenews.com
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - setenews.com
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Finviz
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Limited (NASDAQ: IMMP)Share Price - intelligentinvestor.com.au
Which stocks are moving before the opening bell on Thursday? - ChartMill
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
IMMP Stock Price, Forecast & Analysis | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - Chartmill
Immutep Limited (ASX: IMM) - The Motley Fool Australia
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Technical Analysis of Immutep Ltd Sponsored ADR (NASDAQ:IMMP) - TradingView
IMM Stock Price and Chart — ASX:IMM - TradingView — Track All Markets
IMMP - Finviz
IMMP Stock Price | Immutep Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView — Track All Markets
Zai Lab Limited (ZLAB) stock price, news, quote and history - Yahoo Finance UK
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Immutep ADR Share Price Today | NASDAQ: IMMP Stock - Investing.com India
Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia
Immutep Limited Adr Stock (IMMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):